Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cohort profile: an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - the VAccine Study COVID-19 (VASCO).
Huiberts AJ, Hoeve CE, Kooijman MN, de Melker HE, Hahné SJ, Grobbee DE, van Binnendijk R, den Hartog G, van de Wijgert JH, van den Hof S, Knol MJ. Huiberts AJ, et al. Among authors: van den hof s. BMJ Open. 2024 Oct 14;14(10):e085388. doi: 10.1136/bmjopen-2024-085388. BMJ Open. 2024. PMID: 39401962 Free PMC article.
Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021.
de Gier B, Andeweg S, Joosten R, Ter Schegget R, Smorenburg N, van de Kassteele J; RIVM COVID-19 surveillance and epidemiology team 1,; Hahné SJ, van den Hof S, de Melker HE, Knol MJ; Members of the RIVM COVID-19 surveillance and epidemiology team. de Gier B, et al. Among authors: van de kassteele j, van den hof s. Euro Surveill. 2021 Aug;26(31):2100640. doi: 10.2807/1560-7917.ES.2021.26.31.2100640. Euro Surveill. 2021. PMID: 34355689 Free PMC article.
Higher risk of SARS-CoV-2 Omicron BA.4/5 infection than of BA.2 infection after previous BA.1 infection, the Netherlands, 2 May to 24 July 2022.
Andeweg SP, de Gier B, Vennema H, van Walle I, van Maarseveen N, Kusters NE, de Melker HE, Hahné SJ, van den Hof S, Eggink D, Knol MJ. Andeweg SP, et al. Among authors: van maarseveen n, van walle i, van den hof s. Euro Surveill. 2023 Feb;28(7):2200724. doi: 10.2807/1560-7917.ES.2023.28.7.2200724. Euro Surveill. 2023. PMID: 36795499 Free PMC article.
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022.
Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahné SJ, den Hartog G, van de Wijgert JH, van den Hof S, Knol MJ. Huiberts AJ, et al. Among authors: den hartog g, van den hof s, van de wijgert jh. Euro Surveill. 2023 Feb;28(7):2300087. doi: 10.2807/1560-7917.ES.2023.28.7.2300087. Euro Surveill. 2023. PMID: 36795500 Free PMC article.
Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study.
Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahné SJM, den Hartog G, Grobbee DE, van de Wijgert JHHM, van den Hof S, Knol MJ. Huiberts AJ, et al. Among authors: van de wijgert jhhm, den hartog g, van den hof s. Int J Infect Dis. 2023 Aug;133:36-42. doi: 10.1016/j.ijid.2023.04.401. Epub 2023 Apr 20. Int J Infect Dis. 2023. PMID: 37086863 Free PMC article.
Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022.
de Gier B, van Asten L, Boere TM, van Roon A, van Roekel C, Pijpers J, van Werkhoven CHH, van den Ende C, Hahné SJM, de Melker HE, Knol MJ, van den Hof S. de Gier B, et al. Among authors: van roon a, van roekel c, van werkhoven chh, van den ende c, van asten l, van den hof s. Vaccine. 2023 Jul 12;41(31):4488-4496. doi: 10.1016/j.vaccine.2023.06.005. Epub 2023 Jun 8. Vaccine. 2023. PMID: 37328352 Free PMC article.
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.
Huiberts AJ, Hoeve CE, de Gier B, Cremer J, van der Veer B, de Melker HE, van de Wijgert JH, van den Hof S, Eggink D, Knol MJ. Huiberts AJ, et al. Among authors: van den hof s. Euro Surveill. 2024 Mar;29(10):2400109. doi: 10.2807/1560-7917.ES.2024.29.10.2400109. Euro Surveill. 2024. PMID: 38456217 Free PMC article.
Health-related quality of life during the COVID-19 pandemic: The impact of restrictive measures using data from two Dutch population-based cohort studies.
van Hagen CCE, Huiberts AJ, Mutubuki EN, de Melker HE, Vos ERA, van de Wijgert JHHM, van den Hof S, Knol MJ, van Hoek AJ. van Hagen CCE, et al. Among authors: van den hof s. PLoS One. 2024 Mar 18;19(3):e0300324. doi: 10.1371/journal.pone.0300324. eCollection 2024. PLoS One. 2024. PMID: 38498510 Free PMC article.
165 results